Government Cancer Tech Available for Biotech License
Published Date: 7/16/2026
Notice
Summary
The National Cancer Institute has invented a cool new way to grow special immune cells called TCR-T cells that can better fight cancer. This method helps companies make more powerful, targeted cell therapies by boosting the right cells and cutting out the extras. If you’re in biotech or cancer treatment, this is your chance to license a game-changing tool that could speed up cancer cures and bring new treatments to patients faster.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NCI TCR-T Method Available to License
The National Cancer Institute is offering a government-owned method (NIH Reference Number E-143-2024-0) for license to companies interested in commercializing TCR-engineered T cells. Interested parties can contact Andrew Burke, Ph.D., at [email protected] or 240-276-5484 to pursue licensing for a Clinical Phase II technology.
Manufacturing Method Yields Highly Enriched Cells
The method uses irradiated feeder cells and an anti-mouse TCR beta constant region antibody (for example, H57) in place of OKT3 to selectively expand murine-human hybrid TCR-expressing T cells under GMP conditions. This process produces a cell product highly enriched for the engineered cells, which improves manufacturing quality for companies making personalized adoptive cell therapies.
Potential Improved Therapeutic Benefit for Patients
NCI reports that T cells produced with this method show increased persistence, improved surface expression of the therapeutic TCR alpha/beta, and reduced risk of mis-pairing with endogenous chains. These features are described as increasing therapeutic benefit for adoptive cell transfer in oncology applications.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14347 — Government Owned Invention Available for License: Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients With Chronic Viral Infection(s)
The National Cancer Institute has created a new way to make special immune cells called PILs that can fight chronic HPV infections causing painful growths in the throat and genital areas. This new cell therapy could reduce the need for repeated surgeries, improving patients’ lives and cutting healthcare costs. Researchers are now looking for partners to help develop and license this promising treatment soon.
2026-14242 — National Institute on Minority Health and Health Disparities; Notice of Partially Closed Meeting
The National Institute on Minority Health and Health Disparities is holding a virtual meeting on August 31, 2026, to discuss important health topics and review grant applications. The first part of the meeting is open to the public and will be streamed online, while the last hour is closed to protect private info and trade secrets. This meeting affects researchers and communities focused on minority health and could influence future funding decisions.
2026-14133 — Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering new, powerful antibodies for licensing that help the immune system fight cancer better by releasing its natural brakes. This opportunity is perfect for companies ready to bring cutting-edge cancer treatments to market faster, with some international patent options available. Interested parties should act soon to explore this exciting tech and start making a difference—and money!
2026-14001 — National Human Genome Research Institute; Notice of Meeting
The National Human Genome Research Institute is holding a public meeting on September 28-29, 2026, to share updates and review grant applications. Scientists, researchers, and anyone interested in human genetics can join in person or online. This meeting helps decide which projects get funding, so it impacts future research and innovation in genetics.
2026-14003 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review and decide on important research grant applications. These meetings keep sensitive info private, protecting ideas and personal details. Scientists applying for grants and the research community will feel the impact as funding decisions get made on time.
2026-13802 — Government Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
The National Institutes of Health is offering special mouse strains that help study a rare heart rhythm disorder called CPVT. These mice let scientists explore how a key heart gene works and test new gene therapies. Researchers interested in this tool can access it now—no patents, just pure science ready to speed up discoveries!
Previous / Next Documents
Previous: 2026-14345 — United States of America, et al. v. RealPage, Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
The U.S. government is stopping Willow Bridge Property Company from using RealPage’s pricing software that shares sensitive info with other landlords. This change will help keep rental prices fair and competitive. Willow Bridge must also follow new rules and work with the government, with public comments open for 60 days.
Next: 2026-14347 — Government Owned Invention Available for License: Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients With Chronic Viral Infection(s)
The National Cancer Institute has created a new way to make special immune cells called PILs that can fight chronic HPV infections causing painful growths in the throat and genital areas. This new cell therapy could reduce the need for repeated surgeries, improving patients’ lives and cutting healthcare costs. Researchers are now looking for partners to help develop and license this promising treatment soon.